We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
France’s competition agency, Conseil de la Concurrence, has fined GlaxoSmithKline PLC 10 million in the country’s first-ever prosecution for predatory pricing
It is not necessary within the meaning of Article L. 713-6 of the French Intellectual Property Code (“CPI”) to mention the brand of the reference product in comparative advertising for a generic medicine, as the healthcare professionals to which the advertising is directed have other means (namely, the INN - international non-proprietary name) by which to identify the corresponding reference product
